Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance

Antonios Chatzigeorgiou, Tom Seijkens, Barbara Zarzycka, David Engel, Marjorie Poggi, Susan Van Den Berg, Sjoerd Van Den Berg, Oliver Soehnlein, Holger Winkels, Linda Beckers, Dirk Lievens, Ann Driessen, Pascal Kusters, Erik Biessen, Ruben Garcia-Martin, Anne Klotzsche Von Ameln, Marion Gijbels, Randolph Noelle, Louis Boon, Tilman HackengKlaus Schulte, Aimin Xu, Gert Vriend, Sander Nabuurs, Kyoung Jin Chung, Ko Willems Van Dijk, Patrick C N Rensen, Norbert Gerdes, Menno De Winther, Norman L Block, Andrew V Schally, Christian Weber, Stefan R. Bornstein, Gerry Nicolaes, Triantafyllos Chavakis, Esther Lutgens

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

The immune system plays an instrumental role in obesity and insulin resistance. Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced obesity (DIO). Although not exhibiting increased weight gain, male CD40-/- mice in DIO displayed worsened insulin resistance, compared with wild-type mice. This worsening was associated with excessive inflammation of adipose tissue (AT), characterized by increased accumulation of CD8+ T cells and M1 macrophages, and enhanced hepatosteatosis. Mice with deficient CD40- TRAF2/3/5 signaling in MHCII+ cells exhibited a similar phenotype in DIO as CD40-/- mice. In contrast, mice with deficient CD40-TRAF6 signaling in MHCII+ cells displayed no insulin resistance and showed a reduction in both AT inflammation and hepatosteatosis in DIO. To prove the therapeutic potential of inhibition of CD40-TRAF6 in obesity, DIO mice were treated with a small-molecule inhibitor that we designed to specifically block CD40-TRAF6 interactions; this compound improved insulin sensitivity, reduced AT inflammation, and decreased hepatosteatosis. Our study reveals that the CD40-TRAF2/ 3/5 signaling pathway in MHCII+ cells protects against AT inflammation and metabolic complications associated with obesity whereas CD40-TRAF6 interactions in MHCII+ cells aggravate these complications. Inhibition of CD40-TRAF6 signaling by our compound may provide a therapeutic option in obesity-associated insulin resistance.

Original languageEnglish
Pages (from-to)2686-2691
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number7
DOIs
StatePublished - Feb 18 2014

Fingerprint

TNF Receptor-Associated Factor 6
Insulin Resistance
Obesity
Adipose Tissue
Diet
TNF Receptor-Associated Factor 2
Inflammation
Therapeutics
Tumor Necrosis Factor Receptor-Associated Peptides and Proteins
Weight Gain
Immune System
Macrophages

Keywords

  • Immunity
  • Metabolism
  • Type 2 diabetes

ASJC Scopus subject areas

  • General

Cite this

Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. / Chatzigeorgiou, Antonios; Seijkens, Tom; Zarzycka, Barbara; Engel, David; Poggi, Marjorie; Van Den Berg, Susan; Van Den Berg, Sjoerd; Soehnlein, Oliver; Winkels, Holger; Beckers, Linda; Lievens, Dirk; Driessen, Ann; Kusters, Pascal; Biessen, Erik; Garcia-Martin, Ruben; Ameln, Anne Klotzsche Von; Gijbels, Marion; Noelle, Randolph; Boon, Louis; Hackeng, Tilman; Schulte, Klaus; Xu, Aimin; Vriend, Gert; Nabuurs, Sander; Chung, Kyoung Jin; Van Dijk, Ko Willems; Rensen, Patrick C N; Gerdes, Norbert; De Winther, Menno; Block, Norman L; Schally, Andrew V; Weber, Christian; Bornstein, Stefan R.; Nicolaes, Gerry; Chavakis, Triantafyllos; Lutgens, Esther.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 7, 18.02.2014, p. 2686-2691.

Research output: Contribution to journalArticle

Chatzigeorgiou, A, Seijkens, T, Zarzycka, B, Engel, D, Poggi, M, Van Den Berg, S, Van Den Berg, S, Soehnlein, O, Winkels, H, Beckers, L, Lievens, D, Driessen, A, Kusters, P, Biessen, E, Garcia-Martin, R, Ameln, AKV, Gijbels, M, Noelle, R, Boon, L, Hackeng, T, Schulte, K, Xu, A, Vriend, G, Nabuurs, S, Chung, KJ, Van Dijk, KW, Rensen, PCN, Gerdes, N, De Winther, M, Block, NL, Schally, AV, Weber, C, Bornstein, SR, Nicolaes, G, Chavakis, T & Lutgens, E 2014, 'Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 7, pp. 2686-2691. https://doi.org/10.1073/pnas.1400419111/-/DCSupplemental
Chatzigeorgiou, Antonios ; Seijkens, Tom ; Zarzycka, Barbara ; Engel, David ; Poggi, Marjorie ; Van Den Berg, Susan ; Van Den Berg, Sjoerd ; Soehnlein, Oliver ; Winkels, Holger ; Beckers, Linda ; Lievens, Dirk ; Driessen, Ann ; Kusters, Pascal ; Biessen, Erik ; Garcia-Martin, Ruben ; Ameln, Anne Klotzsche Von ; Gijbels, Marion ; Noelle, Randolph ; Boon, Louis ; Hackeng, Tilman ; Schulte, Klaus ; Xu, Aimin ; Vriend, Gert ; Nabuurs, Sander ; Chung, Kyoung Jin ; Van Dijk, Ko Willems ; Rensen, Patrick C N ; Gerdes, Norbert ; De Winther, Menno ; Block, Norman L ; Schally, Andrew V ; Weber, Christian ; Bornstein, Stefan R. ; Nicolaes, Gerry ; Chavakis, Triantafyllos ; Lutgens, Esther. / Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 7. pp. 2686-2691.
@article{58284bba8d75485297d7d5abaefb84c3,
title = "Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance",
abstract = "The immune system plays an instrumental role in obesity and insulin resistance. Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced obesity (DIO). Although not exhibiting increased weight gain, male CD40-/- mice in DIO displayed worsened insulin resistance, compared with wild-type mice. This worsening was associated with excessive inflammation of adipose tissue (AT), characterized by increased accumulation of CD8+ T cells and M1 macrophages, and enhanced hepatosteatosis. Mice with deficient CD40- TRAF2/3/5 signaling in MHCII+ cells exhibited a similar phenotype in DIO as CD40-/- mice. In contrast, mice with deficient CD40-TRAF6 signaling in MHCII+ cells displayed no insulin resistance and showed a reduction in both AT inflammation and hepatosteatosis in DIO. To prove the therapeutic potential of inhibition of CD40-TRAF6 in obesity, DIO mice were treated with a small-molecule inhibitor that we designed to specifically block CD40-TRAF6 interactions; this compound improved insulin sensitivity, reduced AT inflammation, and decreased hepatosteatosis. Our study reveals that the CD40-TRAF2/ 3/5 signaling pathway in MHCII+ cells protects against AT inflammation and metabolic complications associated with obesity whereas CD40-TRAF6 interactions in MHCII+ cells aggravate these complications. Inhibition of CD40-TRAF6 signaling by our compound may provide a therapeutic option in obesity-associated insulin resistance.",
keywords = "Immunity, Metabolism, Type 2 diabetes",
author = "Antonios Chatzigeorgiou and Tom Seijkens and Barbara Zarzycka and David Engel and Marjorie Poggi and {Van Den Berg}, Susan and {Van Den Berg}, Sjoerd and Oliver Soehnlein and Holger Winkels and Linda Beckers and Dirk Lievens and Ann Driessen and Pascal Kusters and Erik Biessen and Ruben Garcia-Martin and Ameln, {Anne Klotzsche Von} and Marion Gijbels and Randolph Noelle and Louis Boon and Tilman Hackeng and Klaus Schulte and Aimin Xu and Gert Vriend and Sander Nabuurs and Chung, {Kyoung Jin} and {Van Dijk}, {Ko Willems} and Rensen, {Patrick C N} and Norbert Gerdes and {De Winther}, Menno and Block, {Norman L} and Schally, {Andrew V} and Christian Weber and Bornstein, {Stefan R.} and Gerry Nicolaes and Triantafyllos Chavakis and Esther Lutgens",
year = "2014",
month = "2",
day = "18",
doi = "10.1073/pnas.1400419111/-/DCSupplemental",
language = "English",
volume = "111",
pages = "2686--2691",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "7",

}

TY - JOUR

T1 - Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance

AU - Chatzigeorgiou, Antonios

AU - Seijkens, Tom

AU - Zarzycka, Barbara

AU - Engel, David

AU - Poggi, Marjorie

AU - Van Den Berg, Susan

AU - Van Den Berg, Sjoerd

AU - Soehnlein, Oliver

AU - Winkels, Holger

AU - Beckers, Linda

AU - Lievens, Dirk

AU - Driessen, Ann

AU - Kusters, Pascal

AU - Biessen, Erik

AU - Garcia-Martin, Ruben

AU - Ameln, Anne Klotzsche Von

AU - Gijbels, Marion

AU - Noelle, Randolph

AU - Boon, Louis

AU - Hackeng, Tilman

AU - Schulte, Klaus

AU - Xu, Aimin

AU - Vriend, Gert

AU - Nabuurs, Sander

AU - Chung, Kyoung Jin

AU - Van Dijk, Ko Willems

AU - Rensen, Patrick C N

AU - Gerdes, Norbert

AU - De Winther, Menno

AU - Block, Norman L

AU - Schally, Andrew V

AU - Weber, Christian

AU - Bornstein, Stefan R.

AU - Nicolaes, Gerry

AU - Chavakis, Triantafyllos

AU - Lutgens, Esther

PY - 2014/2/18

Y1 - 2014/2/18

N2 - The immune system plays an instrumental role in obesity and insulin resistance. Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced obesity (DIO). Although not exhibiting increased weight gain, male CD40-/- mice in DIO displayed worsened insulin resistance, compared with wild-type mice. This worsening was associated with excessive inflammation of adipose tissue (AT), characterized by increased accumulation of CD8+ T cells and M1 macrophages, and enhanced hepatosteatosis. Mice with deficient CD40- TRAF2/3/5 signaling in MHCII+ cells exhibited a similar phenotype in DIO as CD40-/- mice. In contrast, mice with deficient CD40-TRAF6 signaling in MHCII+ cells displayed no insulin resistance and showed a reduction in both AT inflammation and hepatosteatosis in DIO. To prove the therapeutic potential of inhibition of CD40-TRAF6 in obesity, DIO mice were treated with a small-molecule inhibitor that we designed to specifically block CD40-TRAF6 interactions; this compound improved insulin sensitivity, reduced AT inflammation, and decreased hepatosteatosis. Our study reveals that the CD40-TRAF2/ 3/5 signaling pathway in MHCII+ cells protects against AT inflammation and metabolic complications associated with obesity whereas CD40-TRAF6 interactions in MHCII+ cells aggravate these complications. Inhibition of CD40-TRAF6 signaling by our compound may provide a therapeutic option in obesity-associated insulin resistance.

AB - The immune system plays an instrumental role in obesity and insulin resistance. Here, we unravel the role of the costimulatory molecule CD40 and its signaling intermediates, TNF receptor-associated factors (TRAFs), in diet-induced obesity (DIO). Although not exhibiting increased weight gain, male CD40-/- mice in DIO displayed worsened insulin resistance, compared with wild-type mice. This worsening was associated with excessive inflammation of adipose tissue (AT), characterized by increased accumulation of CD8+ T cells and M1 macrophages, and enhanced hepatosteatosis. Mice with deficient CD40- TRAF2/3/5 signaling in MHCII+ cells exhibited a similar phenotype in DIO as CD40-/- mice. In contrast, mice with deficient CD40-TRAF6 signaling in MHCII+ cells displayed no insulin resistance and showed a reduction in both AT inflammation and hepatosteatosis in DIO. To prove the therapeutic potential of inhibition of CD40-TRAF6 in obesity, DIO mice were treated with a small-molecule inhibitor that we designed to specifically block CD40-TRAF6 interactions; this compound improved insulin sensitivity, reduced AT inflammation, and decreased hepatosteatosis. Our study reveals that the CD40-TRAF2/ 3/5 signaling pathway in MHCII+ cells protects against AT inflammation and metabolic complications associated with obesity whereas CD40-TRAF6 interactions in MHCII+ cells aggravate these complications. Inhibition of CD40-TRAF6 signaling by our compound may provide a therapeutic option in obesity-associated insulin resistance.

KW - Immunity

KW - Metabolism

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84894377101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894377101&partnerID=8YFLogxK

U2 - 10.1073/pnas.1400419111/-/DCSupplemental

DO - 10.1073/pnas.1400419111/-/DCSupplemental

M3 - Article

C2 - 24492375

AN - SCOPUS:84894377101

VL - 111

SP - 2686

EP - 2691

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 7

ER -